MES-1022 is under clinical development by Mesentech and currently in Phase I for Bone Fracture. According to GlobalData, Phase I drugs for Bone Fracture does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the MES-1022 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MES-1022 overview

MES-1022 is under development for the treatment of bone fractures. The drug candidate is a prodrug comprising, prostaglandin mimetic conjugated with a targeting moiety that binds to bone. It is administered through subcutaneous route and acts by targeting PGE2 receptor 4 (EP4). It is being developed based on tissue-selective prodrug technology.

Mesentech overview

Mesentech is a Pharmaceuticals and Healthcare company that provides Health care and drug Development services. The company is Headquartered in Vancouver, British Columbia, Canada.

For a complete picture of MES-1022’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.